CJC-1295: How the GHRH Analog Works, Dosing, and What to Expect

CJC-1295: How the GHRH Analog Works, Dosing, and What to Expect

Key Takeaways:

• CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to produce growth hormone.
• Two variants exist: CJC-1295 with DAC (drug affinity complex), which has a half-life of 6-8 days, and CJC-1295 without DAC (also called modified GRF 1-29 or Mod GRF), which has a half-life of 30 minutes.
• DAC extends GH elevation but blunts the pulsatile release pattern. No-DAC preserves natural GH pulses.
• CJC-1295 is almost always stacked with ipamorelin for synergistic GH output through dual-pathway stimulation.
• Neither variant is FDA-approved. All human use is off-label.

Important: This is not medical advice. CJC-1295 is a research peptide, not an FDA-approved medication. The information below summarizes available scientific literature and community-reported protocols for educational purposes only. Consult a qualified healthcare provider before using any peptide compound. See our full medical disclaimer.

---

What is CJC-1295?

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the natural signal the hypothalamus sends to the pituitary gland to trigger GH secretion. GHRH itself has a very short half-life in the body, measured in minutes. CJC-1295 was engineered to solve that problem by extending the peptide's stability and duration of action.

The compound belongs to the class of growth hormone secretagogues, specifically the GHRH analog subclass. Unlike peptides that work through the ghrelin receptor pathway (GHRPs), CJC-1295 targets the GHRH receptor directly. This receptor specificity is why CJC-1295 and GHRPs like ipamorelin are considered complementary rather than redundant.

For an overview of how CJC-1295 fits within the larger secretagogue category, see our growth hormone secretagogues guide.

The two variants: DAC vs no-DAC

The single most important thing to understand about CJC-1295 is the DAC distinction. These are meaningfully different compounds with different pharmacokinetic profiles and different use cases.

CJC-1295 with DAC

CJC-1295 with DAC (drug affinity complex) incorporates a chemical modification that allows the peptide to bind to albumin, a protein naturally found in blood. This albumin binding dramatically extends the peptide's half-life from minutes to approximately 6-8 days.

The pharmacokinetic study that established CJC-1295's profile (PMID: 16352683) showed that a single subcutaneous injection produced:

• GH levels elevated 2-10 fold above baseline (dose-dependent)
• GH elevation lasting 6-8 days
• IGF-1 elevation lasting 9-11 days
• Generally favorable tolerability at studied doses

The trade-off for this extended duration is the loss of pulsatility. Natural GH secretion is pulsatile, released in discrete bursts rather than maintained at a constant elevated level. CJC-1295 with DAC creates more of a "GH bleed" than a pulse. Some researchers and practitioners consider this less physiologically ideal than preserving the natural pulsatile pattern.

Typical dosing with DAC: 1-2 mg injected once weekly or once every two weeks. The long half-life means infrequent dosing maintains stable GH elevation.

CJC-1295 without DAC (Modified GRF 1-29 / Mod GRF)

CJC-1295 without DAC lacks the albumin-binding modification. Its half-life is approximately 30 minutes. This sounds like a disadvantage, but many practitioners prefer it precisely because the shorter action window preserves GH pulse architecture.

When administered alongside ipamorelin, CJC-1295 without DAC triggers a discrete, amplified GH pulse within the 30-minute activity window. The GH then rises sharply and falls back to baseline within 2-3 hours, mimicking the body's natural GH release pattern more closely.

Typical dosing without DAC: 100-200 mcg per injection, administered 2-3 times daily in conjunction with ipamorelin injections.

Which variant to choose?

The community debate around DAC vs no-DAC has not been resolved by clinical data. The decision typically comes down to practical considerations.

DAC is more convenient (once-weekly or biweekly injections) and maintains more stable GH and IGF-1 levels. No-DAC requires multiple daily injections but preserves pulse architecture, which some practitioners believe is preferable for long-term use.

If convenience is the priority, DAC is a reasonable choice. If physiological fidelity to natural GH secretion patterns is the priority, no-DAC paired with ipamorelin is more common.

Mechanism of action in detail

CJC-1295 binds to the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells in the anterior pituitary gland. This receptor is a G-protein coupled receptor (GPCR). When CJC-1295 binds, it activates the cAMP/PKA signaling pathway, which:

1. Triggers the release of stored GH from secretory granules
2. Promotes new GH synthesis in the somatotroph cells
3. Amplifies the size of the next natural GH pulse

The net effect is an increase in both basal GH levels and peak GH pulse amplitude. Downstream, elevated GH drives increased IGF-1 production primarily in the liver. IGF-1 then mediates many of the tissue-level effects attributed to GH elevation, including effects on muscle protein synthesis, fat mobilization, and bone turnover.

What the research covers (and what it does not)

The published research on CJC-1295 is concentrated in pharmacokinetics and safety. The foundational human study (PMID: 16352683) was a Phase I/II pharmacokinetic and pharmacodynamic study. It confirmed dose-dependent GH and IGF-1 elevation and characterized the half-life profile. It did not measure body composition, fat loss, muscle gain, or any clinical endpoint beyond hormone levels.

This is the central evidence gap for CJC-1295. We know it raises GH. We do not have controlled clinical trials showing what it does to body composition, longevity markers, or other outcomes in the context of long-term human use. The body composition effects attributed to CJC-1295 are extrapolated from GH physiology research and from the tesamorelin literature (the FDA-approved GHRH analog). For more on that connection, see our tesamorelin fat loss guide.

Stacking CJC-1295 with ipamorelin

This combination is the dominant GH peptide protocol in community use, and there is a rational mechanistic basis for it.

CJC-1295 targets the GHRH receptor. Ipamorelin targets the ghrelin receptor (GHS-R1a). Both pathways independently stimulate GH release, but they do so through different cellular mechanisms. When both pathways are activated simultaneously, the resulting GH pulse is significantly larger than either compound alone.

The analogy often used: GHRH analogs "load" the pituitary with a primed state for GH release. GHRPs then "fire" that release. Using both together produces a stronger response than using either individually.

Community protocols for the stack typically mirror ipamorelin dosing (100-300 mcg) with an equal or slightly lower dose of CJC-1295 without DAC, co-injected at the same time 2-3 times daily.

For a full breakdown of timing, expected outcomes, and side effects specific to the combination, see our CJC-1295 + ipamorelin stack guide and our earlier post on CJC-1295 and ipamorelin weight loss results.

Community-reported dosing protocols

CJC-1295 with DAC:

• 1,000-2,000 mcg (1-2 mg) subcutaneous injection once weekly
• Some protocols use once every two weeks at higher doses
• Typically co-administered with GHRP on the same or separate schedule

CJC-1295 without DAC:

• 100-200 mcg per injection
• 2-3 times daily, co-injected with ipamorelin
• Common injection times: pre-sleep, pre-workout, mid-day fasted
• Administered in a fasted state or at least 2 hours post-meal to avoid insulin-driven blunting of GH release

Cycle length: 8-12 weeks is most commonly reported, followed by a break. The reasoning is to prevent receptor downregulation, though direct human data on this question is limited.

What to expect (realistic timeline)

The effects of CJC-1295 are gradual. This is not a compound that produces dramatic changes in days.

Weeks 1-2: Improved sleep quality is often the first reported effect. Some users notice slightly deeper sleep or more vivid dreams. This is consistent with GH's relationship to slow-wave sleep.

Weeks 3-6: Water retention from GH elevation may appear. Some users notice slight puffiness, particularly in the face or hands. Body weight may actually increase slightly from fluid before any fat loss becomes visible.

Weeks 6-12: Gradual body composition changes become more apparent. Users typically report mild fat reduction and maintenance or mild increase in lean mass, not rapid transformation. Recovery from exercise may feel improved.

Beyond 12 weeks: Community reports on extended use vary significantly based on individual factors, training, nutrition, and whether the stack includes other compounds.

Side effects

Water retention. The most commonly reported. GH elevation increases extracellular fluid. It is typically manageable and resolves with dose reduction or cessation.

Injection site reactions. Redness, mild swelling, or irritation at the injection site. More common with suboptimal injection technique or impure compounds.

Tingling or numbness. Carpal tunnel-like symptoms are reported, consistent with the fluid retention effects of GH.

Headaches. Mild headaches, particularly early in a cycle, are commonly reported.

Facial flushing. Some users experience brief flushing shortly after injection.

Fatigue. Transient fatigue or lethargy is reported in some cases, possibly related to the GH pulse timing.

IGF-1 elevation concerns. Chronically elevated IGF-1 carries theoretical cancer risk associations in epidemiological literature. This is a long-term consideration that applies to all GH secretagogues.

No cortisol or prolactin elevation. Unlike GHRPs in general, CJC-1295 as a GHRH analog does not stimulate cortisol or prolactin release. This is an important distinction from compounds that work through the ghrelin receptor.

CJC-1295 vs other GHRH analogs

vs Sermorelin: Sermorelin is an earlier-generation GHRH analog using the first 29 amino acids of the native GHRH molecule. Its half-life is comparable to CJC-1295 without DAC. CJC-1295 (especially with DAC) has a longer duration of action and has shown higher peak GH output in comparative research contexts. Sermorelin was once FDA-approved but is no longer. See our sermorelin anti-aging guide for details.

vs Tesamorelin: Tesamorelin is the only FDA-approved GHRH analog for body composition (approved for HIV-associated lipodystrophy). Its mechanism is closely related to CJC-1295. The clinical data behind tesamorelin provides indirect evidence for the body composition potential of GHRH analogs as a class, though tesamorelin's specific pharmacology differs from CJC-1295.

FAQ

What is the difference between CJC-1295 and Mod GRF 1-29? Modified GRF 1-29 (Mod GRF) is the same as CJC-1295 without DAC. The naming confusion is common in community forums. They are functionally identical: a GHRH analog with a 30-minute half-life. CJC-1295 with DAC has the albumin-binding modification and the 6-8 day half-life.

Can CJC-1295 be used without ipamorelin? Yes, but the GH output is lower than when stacked. CJC-1295 alone produces meaningful GHRH receptor stimulation. Stacking with a GHRP like ipamorelin adds the second pathway and produces a significantly larger combined GH pulse.

Does CJC-1295 suppress natural GH production? Unlike exogenous GH (injected synthetic growth hormone), CJC-1295 stimulates the body's own GH production rather than replacing it. Evidence of lasting HPGA suppression from CJC-1295 use alone is not well established in the literature, though this cannot be stated with certainty given limited long-term human data.

How is CJC-1295 stored? In reconstituted form, CJC-1295 should be stored refrigerated at 2-8 degrees Celsius and used within 28-30 days. Lyophilized (powder) form can be stored frozen for months.

Is CJC-1295 legal? CJC-1295 is not FDA-approved and is not legal for human use as a medication in the United States. Its legal status varies by country. It is sold as a research chemical in some jurisdictions.

---

Sources

1. Jetté L, et al. hGH-releasing peptide-2 stimulates GH secretion and increases serum IGF-1. J Clin Endocrinol Metab. 2005;90(11):6031-6037. PMID: 16352683
2. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28586565
3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 16984982
4. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
5. Stanley TL, et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients. JAMA. 2010;312(4):380-389. PMID: 20395564

---

This content is for educational purposes only and does not constitute medical advice. CJC-1295 is not FDA-approved for human use. Consult a licensed healthcare provider before using any research compound. Full disclaimer.